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Abstract 
The ability to specifically silence genes using siRNA has enormous potential for treating 
genetic diseases. However, siRNA instability and biodistribution issues still need to be overcome, 
and adequate delivery vehicles have proven indispensable in conveying siRNA to its target. 
Chitosan is a promising biopolymer for siRNA delivery, its interest stemming from its safety, 
biodegradability, mucoadhesivity, permeation enhancing effect and cationic charge, as well as 
amenability to undergo chemical modifications. Chitosan and its derivatives can be readily arranged 
into complexes or nanoparticles able to entrap and carry siRNA. Specific strategies have been 
adopted to improve chitosan-based vectors with regard to transfectability. However, further efforts 
are required to verify their value and adapt them to enhance therapeutic output prior to clinical 
application. This review emphasizes the potential of chitosan and its derivatives to develop 
nanocarriers for siRNA delivery. The properties of chitosan that are significant for transfectability 
and the most relevant findings are assessed.  
 
Key words: Chitosan, Chitosan derivatives, Formulation parameters, Gene silencing, Nanocarriers, 
siRNA Delivery 
 
1. Introduction 
Recently, the world has witnessed an explosion of knowledge concerning RNA and DNA-
based diverse functionalities in molecular biology and their potential in therapeutics applications. 
RNA interference (RNAi) therapeutics represents nowadays a potential new class of pharmaceutical 
drugs, arising from the fact that they are easy to design and specific for targeting 1-3. 
Essentially, RNAi is a naturally occurring phenomenon where endogenously processed 
RNA molecules mediate sequence-specific gene regulation. It was first described for the nematode 
worm Caenorhabditis elegans by the Nobel Prizes Craig Mello and Andrew Fire in 1998 3. This 
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mechanism is triggered by antisense molecules like oligonucleotides, aptamers, shRNA (short 
hairpin RNA), microRNA, siRNA (small interfering double-stranded RNA) and ribozymes 2,4, 
that target a complementary messenger RNA (mRNA). In early 2000, siRNA was interestingly 
shown to mediate sequence-specific translational block of the target mRNA in mammalian cells in 
vitro; and, was successfully delivered to mice. Fascinatingly, some of siRNA-based therapeutics is 
actually in clinical trials, mostly directed to ocular treatment. The first clinical assessment of 
siRNA-based on human therapeutics occurred in 2004 and was directed at the treatment of wet age-
related macular degeneration, whereas Vitravene® is the first siRNA-based product available on the 
market for the treatment of cytomegalovirus-induced retinitis in AIDS patients. The first systemic 
siRNA administration of siRNA in non-human primates was reported in 2007 [4-7].  
The antisense function of siRNA can be exogenously induced by the introduction of 
chemically (preformed) or enzymatically (expressed intracellularly via DNA vector) synthesized 
siRNAs, yielding transient or more durable knockdown, respectively 6. These simulate the RNAi 
machinery in eukaryotics where suppression of target genes is achieved through excising long 
double-stranded RNAs into siRNAs, by a cytoplasmic ribonuclease action called dsRNA-specific 
RNaseIII enzyme dicer. This mechanism results in a transient and reversible RNAi effect. Also, 
intracellular generation of siRNA could be endogenously induced via plasmid or virus-driven precursor 
small hairpin RNAs, named natural dsRNA-encoding genes or microRNA genes (miRNAs). They 
result in long lasting effects (weeks or months) and, thereby, could be useful for chronic diseases 
such as cancer 6. Moreover, they require multiple enzymatic steps prior to targeting mRNA 
degradation (transcription, nuclear export and dicer processing) 9. In either case, the double-
stranded RNAs (dsRNAs) of 21-23 nucleotides associate in the cytoplasm with a protein complex 
called RNA-induced silencing complex (RISC); the multiple-turnover enzyme complex that 
mediates endonucleolytic cleavage in the RNAi pathway. siRNA is loaded onto Argonaute 2 
(Ago2), which is the core catalytic component of RISC required for the unwinding of siRNA duplex 
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and, consequently, assembling of siRNA into RISC. RISC subsequently cleaves and releases one 
strand of siRNA (passenger strand), resulting in an activated form of RISC with the other single-
strand (guide siRNA) that directs the specificity of the targeted mRNA recognition through 
complementary base pairing. Another enzyme of RISC, called endonuclease, cleaves the 
phosphodiester bond on the mRNA in the middle of the siRNA-mRNA recognition site, releasing 
the cleaved mRNA fragments (between bases 10 and 11 relative to the 5′ end of the siRNA 
antisense strand) 10-13.This step leads to mRNA degradation (in the case of siRNAs) and/or 
translational repression by binding to the 3′ untranslated region (UTR) (in the case of miRNAs) and, 
eventually gene silencing 6,8,9,14. The siRNA loaded RISC can be recycled for multiple rounds of 
silencing; a feature that makes siRNA more tempting for therapeutic purposes because very small 
siRNA doses are required to achieve the desired effect. This also results in reduced costs and 
possible concentration-dependent off-target effects. It is worth noting that the ability of siRNA to 
form a hybrid with the targeted mRNA depends on its sequence specificity, as well as its affinity, 
which is determined by the number of H bonding formed between siRNA and the targeted sequence 
12. 
Compared to other antisense molecules, siRNA comprises of a larger portion of the RNA 
interference pathway that induces sequence-specific inhibition of gene expression, showing perfect 
complementarity to the target mRNA. It is also regarded as potent since only a few molecules of 
siRNA per cell are required to produce the antisense effect 15. Apart from its low molecular 
weight (Mw), which is 100 times lower than, for example, shRNA, it acts in the cytosol rather than 
in the nucleus, which implies facing fewer obstacles during delivery 13. Besides, siRNAs are easy 
to design and selectively specific for targeting 16-18. In light of these findings, siRNA has proved 
to be more efficient in gene silencing than other RNAi molecules and opened wide perspectives in 
therapeutics for the treatment of any disease that is linked to elevated expression of an identified 
gene, such as cancer, infectious, inflammatory and neurodegenerative diseases. However, the most 
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challenging issue in the siRNA-based therapy is its delivery to the target site, particularly due to the 
lack of stability of siRNA in physiological fluids and the poor penetration into cells. As it is known, 
gene delivery is, generally, a multistep process, thus facing many extra- and intracellular difficulties 
concerning the transport of therapeutic nucleic acids to the targets; a consequence which has 
spurred research to seek out novel delivery strategies. In addition to the hurdles related to the 
siRNA nature, other challenges may depend on both the target organ and the route of 
administration, this being less pronounced in the case of locoregional delivery 13. Excitingly, 
there have been many innovative technologies focusing on solving this issue which have met the 
necessary requirements related to the carriers used, the route of administration and the specific 
target 9.  
The delivery systems proposed so far include viral 19 and non-viral vectors, the latter 
being based on nucleic acids 20 or encapsulation within a carrier system. The approach of non-
viral carrier design requires the use of materials such as cationic lipids 21, polymers 22, 
dendrimers 23, proteins and peptides 24 as well as metallic nanoconstructs 25 and polyamino 
acids 26, mainly in the form of nanoparticulate systems [11,12,27]. Interestingly, matrix-based 
siRNA delivery using tissue engineering scaffolds has been also explored, taking advantage of 
sustained release and high payload protection conferred by such devices [28]. Noteworthy, an 
effective delivery system must exhibit low toxicity, high siRNA encapsulation efficiency, siRNA 
stabilization during either processing or delivery, long circulation time, cell-specific recognition, 
capacity for cellular internalization, endosomal release and cytoplasmic localization with efficient 
dissociation prior to acting on the target [6,8,9,29-31]. Thus, the carrier may enable precise control 
over the onset and duration of antisense action, resulting in a high and more long-lasting therapeutic 
output. In addition to these chemical-based methods, siRNA delivery has also been described using 
physical methods, such as hydrodynamic delivery, which is still restricted to animal application 
[32], and electroporation [33]. Due to concerns associated with the application of viral vectors, 
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including mutagenesis, immunogenicity and pathogenesis [34], together with the recognized 
toxicity and low physical stability of cationic lipids, siRNA delivery strategies lean towards the 
development of polymeric vectors, considering their ease of preparation, compared to the 
aforementioned vectors, and the possibility of conceiving multifunctional delivery to substantiate 
siRNA therapy in vivo. In this context, chitosan is positioned as outstanding candidate given its 
interesting properties for siRNA packaging or encapsulation and cellular uptake, as demonstrated 
by the extensive researches investigating this polymer for siRNA delivery purposes [30,35]. 
This review article highlights the interest of the cationic polymer chitosan as a potential 
nanovector for siRNA delivery. We present an overview of the efforts done to potentiate the role of 
chitosan in gene silencing through addressing parameters related to its formulation and structure, 
namely derivatization, elucidating the consequent effects both in vitro and in vivo. In addition, 
insights into structure-activity relationship and the state-of- the art of siRNA delivery systems based 
on chitosan will be provided.  
 
2. Role of nanotechnology in siRNA delivery 
As stated above, siRNA delivery is confronted with several hurdles related to either the 
siRNA nature or the physiological barriers. Moreover, the physicochemical properties of siRNA, 
such as hydrophilicity, high molecular weight and negative charge [11-13], render poor cell 
penetration followed by low transfectivity when administered as a naked molecule [36-38]. 
Nanotechnology tools have been beneficial in circumventing these obstacles, which can be 
summarized as follows: 
a) Potential siRNA toxicity: in spite of its reported safety, due to the metabolism of natural 
nucleotides in cells, siRNA potential toxicity may arise from the induction of innate immunity, off-
target gene silencing and competition with endogenous RNAi components (e.g. miRNAs) for 
limited RNAi pathways. This potential toxicity originates from some immunostimulatory motifs 
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during siRNA design, and can be fortunately solved by chemical modification which results in a 
higher therapeutic effect at smaller doses and also provides selectivity, evading interference with 
other RNAi molecules [6,13,36]. 
b) Extracellular barriers: it is worth mentioning that most tissues are not easily accessible 
and require the development of effective delivery vehicles. The implement of nanotechnology, to 
design siRNA nanocarriers, has become appealing in order to overcome these barriers which 
hamper transport and stability and, consequently ensure sufficient siRNA delivery with maintained 
integrity. Extracellular barriers, if systemic administration is intended, encompass interactions with 
body enzymes like nucleases and proteins as well as removal by glomerular filtration [13]. 
Furthermore, the rapid elimination and, hence, short half-lives (around 5 min), of exogenous 
siRNA, require repeated administration to attain a determined therapeutic effect [6,37]. 
c) Targetability: cell-type specific delivery has been tackled using targeting moieties or 
ligands either tagged directly to siRNA or to the siRNA carrier [10,39]. These may include 
antibodies [40,41], ligands [42,43], aptamers of other DNA/RNA hybrids [44] and peptides [45]. 
d) Cellular uptake and intracellular trafficking: challenging barriers impair siRNA delivery 
to the target tissue. Cellular uptake and intracellular trafficking constitute complex steps which 
require specific delivery considerations. In fact, siRNA is internalized into cells via endocytosis 
through endocytotic vesicles that fuse with the early endosomes [2,10,13]. These subsequently 
mature into late endosomes prior to fusing with lysosomes, whose luminal pH is mildly acidic (4.5-
6), thus leading to siRNA degradation and, hence, low bioactivity. Therefore, siRNA must be able 
to escape early from the endosomes, to avoid ending up in the lysosomes. Nonetheless, siRNA 
cellular uptake may be achieved without using the endosomal pathway, which has been postulated 
to occur with, for example, cell penetrating peptides [46] and cholesterol [42].  
For lysosomal escape of siRNA, membrane destabilizing agents have been used to promote 
its release into the cytosol in a sufficient quantity, such as fusogenic peptides [47] and lipids [48], as 
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well as pH-responsive lipids [49] or polymers [18] and reduction-sensitive polymers [50,51]. The 
pH-responsive polymers, containing protonable amines, such as the cationic ones, are hypothesized 
to have a proton sponge effect or buffering capacity whereby proton influx is initiated through a 
vesicular ATPase-driven pump. Then, electrostatic repulsion occurs between the protonated amine 
groups leading to complex swelling or expansion, which results in raising internal osmotic pressure 
and counter-ion penetration to end up with endosomal membrane rupture and, subsequently, siRNA 
release [13,18]. Endosomal escape might also be mediated by reduction, generated through a 
disulfide bond [2]. 
As referred to above, nanotechnology has been providing solutions for bypassing the 
limitations of siRNA delivery, in order to enhance its therapeutic output, by engineering delivery 
approaches particularly endowed with multifunctionality. These strategies may include the direct 
modification of siRNA molecules, which may involve either tailoring the siRNA length [9,14] 
and/or the chemical modification of the siRNA sense strand. This has resulted in enhanced serum 
stability with an increasing half-time in vivo, reduced sequence-dependent off-target effect and 
immunogenicity and, consequently, improved silencing activity [2,8,37]. On the other hand, in order 
to produce a biologically active siRNA, the selection of a proper siRNA sequence is the pivotal step 
in the synthetic siRNA design as this selection mainly depends on that of the targeted mRNA. After 
identifying the sequence to perform the effect of interest, further structural and chemical 
modification for siRNA are still needed to enhance its biological performance in vivo [37]. 
Chemical modification can be achieved by replacing the phosphate backbone through 
phosphorothionate or boranophosphonate linkages, or the 2-hydrocyl group of the ribose sugar with 
2´-amine, 2´-halogen, 2´-O-methyl and locked nucleic acid. In addition, these modifications may 
also be performed on the nucleobase and on the 5´- or 3´- terminus, where end modification of 
siRNA allows conjugation with ligands, antibodies and other targeting moieties [8,9,10]. In this 
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context, it has been found that the sense strand and the terminal regions of siRNA can tolerate more 
modifications than its antisense strand and the central region [8].  
Notwithstanding the possibility of siRNA modification, the molecule is still subject to renal 
filtration when administered to the blood stream, owing to its small size (< 10 nm). Furthermore, a 
poor pharmacokinetic profile is observed due to its polyanionic character, and its conjugation often 
makes endosomal release a difficult task, apart from impairing affinity to the target [10]. Thereby, 
delivery strategies have been pursued to generate new potent vectors, such as the already mentioned 
polymeric vehicles.  
 
3. Interest of chitosan in siRNA delivery systems 
Chitosan is a linear polysaccharide composed of randomly distributed β-(1-4)-linked D-
glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit) (Figure 1) that is 
derived from chitin, and is one of the most promising biopolymers for drug and gene delivery. It has 
been largely investigated owing to its interesting and broad biological activities, which include 
wound healing [52], anti-tumor properties [53], as well as hypocholesterolemic [54], antimicrobial 
[55] and antioxidative [56] effect. It has also been extensively studied for drug delivery purposes, 
demonstrating low toxicity, biodegradability and biocompatibility [57-59], as well as 
mucoadhesivity [60,61] and the enhancement of macromolecules permeation through triggering the 
opening of epithelial tight junctions [62]. The chitosan structure is amenable to chemical 
derivatization; therefore its physicochemical properties can be modulated to fit specific 
requirements that ensure efficient delivery [63]. Chitosan displays a cationic character due to the 
presence of amine groups. This characteristic is essential for siRNA packaging or encapsulation 
which, in turn, provides protection against degradation during either processing or delivery and 
facilitates its cellular uptake, as well as the endosomal escape, due to the buffering capacity of this 
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polymer [30]. It is worth mentioning that chitosan was first employed in gene therapy in 1995 by 
Mumper et al [64]. 
The most popular techniques to prepare chitosan-based siRNA delivery systems comprise of 
polyelectrolyte complexation [38,65], coacervation [17,66] and ionotropic gelation [67,68]. In these 
techniques, electrostatic interactions are involved whereby the positively charged amine groups of 
chitosan interact with the negatively charged phosphate groups of siRNA in addition to the 
crosslinker tripolyphosphate (TPP), in the case of gelation technique [30,63]. During condensation 
reactions, the extended siRNA is transformed into the condensed state, driven by the overall 
increase in the entropy of the system, leading to the counter-ions release which consequently results 
in compaction [69]. The resultant structures are of defined morphology and reduced dimensions, 
thus their cellular uptake is expedited via endocytosis, by shielding the negative charge of siRNA 
that hampers its interaction with biological membranes (typical molecular weight of siRNA is 
approx. 15 kDa) [70,71].  Desolvation has hardly ever been used in this regard [30,72]. Collectively, 
these techniques result in cationic siRNA vehicles, which benefit the interactions with biological 
membranes, as previously mentioned [72,73]. Chitosan-based gene vectors were initially designed 
as polyplexes, resulting from a simple complexation between chitosan and genetic material. After 
that, because of physical and biological problems affecting their ability in gene transfection, 
Köping-Höggård et al. adopted the ionic gelation technique, previously developed for protein 
encapsulation, in order to alternatively incorporate genetic material into nanoparticulate systems 
[74]. siRNA delivery in the form of chitosan nanoparticles was described to enhance cellular uptake 
by up to 1.8-fold compared to the chitosan solution in A459 cells, without notable influence on the 
chitosan toxicity profile [75]. Nevertheless, in a work with murine fibroblasts, Dehousse et al. found 
that higher cell toxicity was observed upon incubation with a solution of trimethylchitosan, 
compared to the nanoparticulate form, probably because the cationic charge is reduced upon 
complexation and nanoparticle formation, decreasing the interaction with cell membrane [27]. 
14 
 
Furthermore, in contrast with the results obtained for the chitosan solution, chitosan nanoparticles 
uptake has shown to be a saturable event, with the binding affinity and uptake capacity decreasing 
with the reduction of polymer molecular weight and degree of deacetylation [76]. The 
internalization of chitosan nanoparticles appeared to predominantly occur by adsorptive 
endocytosis, initiated by non-specific interactions between nanoparticles and cell membranes, and 
was in part mediated by the clathrin-mediated process [75]. Chitosan has been demonstrated to have 
potential in modulating siRNA stability and biodistribution [37].  
In order to investigate the optimal conditions for satisfactory levels of gene transfection, it is 
necessary to study the physicochemical characteristics of chitosan-based siRNA systems through 
the variation of particular parameters and correlate them with transfection efficiency. These 
parameters include the preparation conditions (pH and ionic strength) and mass or N/P ratio (ratio 
of chitosan amino groups to siRNA phosphate groups) [26,67,77 as well as the structural properties 
of chitosan, such as molecular weight (Mw), degree of deacetylation (DD), chitosan type 77,79] 
and chemical modification [27], which affect the specific interaction with siRNA enormously. The 
role of these parameters in transfection efficiency is visible in their direct effect on physicochemical 
properties of chitosan particles that eventually control siRNA delivery kinetics in vivo, including 
cellular interactions [38]. These particle properties encompass particle size, zeta potential and 
stability, as well as the association efficiency of siRNA and binding capacity. Below, a thorough 
description of the various factors referred to which affect siRNA delivery is provided. 
 
3.1. Effect of chitosan molecular weight 
Chitosan Mw has been demonstrated to greatly influence transfection efficiency, as it 
translates to a direct effect on particle size, stability and, consequently, on the siRNA release 
behavior [80]. Techaarpornkul et al. reported that complexes prepared at a chitosan/siRNA weight 
ratio of 32, based on low molecular weight chitosan (LMWC) (20 kDa, DD = 85%) manifested a 
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higher enhanced green fluorescent protein (EGFP) silencing effect than those based on high 
molecular weight chitosan (HMWC) (200 and 460 kDa) in EGFP stably expressing human cervix 
epithelial carcinoma (Hela) cells. In this case, the effective gene knockdown was attributed to the 
smallest sizes of particles based on LMWC, although HMWC resulted in more stable complexes. 
The higher stability observed for complexes of HMWC could be explained by a chain entanglement 
effect, whereby chitosan easily entangles free siRNA, resulting in stronger binding to siRNA and, 
thus increased stability, but reduced siRNA decoupling in the cytosol prior to acting on its target 
mRNA. This might rationalize the lower transfectability of the complexes based on HMWC [79]. 
Another work by the group has drawn the same conclusion in which the effect of chitosan Mw on 
gene silencing activity was also studied. However, on the contrary of what was described in the first 
study, particle size was shown to be dependent on chitosan Mw, between 20 and 200 kDa [16]. The 
proportional correlation between particle size and Mw has been documented in several other works 
[67,81], although in some cases smaller particle sizes were reported with increasing Mw of chitosan 
(from 140 to 250 kDa), possibly due to increased inter-chain connections between longer chitosan 
molecules [82]. Surprisingly, in this latter study, this difference in particle size did not significantly 
affect transfection efficiency; also implying that Mw did not induce differences in the transfection 
level. Nevertheless, transfection was more effective than that of the commercial Lipofectamine 
control [82]. Likewise, other authors report that the transfectability of complexes composed of 
chitosan or trimethyl chitosan/siRNA in HEK293 cells was independent of chitosan Mw (42-400 
kDa, DD = 84-88%) [27]. This may suggest that chitosan Mw will not remarkably affect the 
transfection efficiency by itself. Continuing in the same context, Liu et al. [80] studied differences 
in transfection efficiency resulting from the application of chitosan with variable Mw and DD in 
EGFP expressing H1299 cells (human lung carcinoma cells). In contrast to the aforementioned 
observations, higher gene silencing was found for HMWC, being concomitantly dependent on DD, 
with better transfection results for high DD. To establish this conclusion, chitosan with Mw of 8.9-
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173 kDa was used, and the resulting complexes featured smaller sizes and improved stability at 
higher Mws, which was attributed to the availability of a sufficient chain length and charge density 
to condense siRNA into discrete particles. This indicates that the presence of chitosan chains which 
are long enough, along with H-bonding and the hydrophobic interactions between the sugar residues 
of chitosan as well as the nucleoside bases of siRNA, may further contribute to the mechanism of 
complexes formation. Similarly, HMWC of 140 kDa (DD = 84%) could efficiently knockdown 
EGFP gene in H1299 cells at 50 nM of EGFP-siRNA, thus being comparable with the TransIT-
TKO siRNA transfection agent. It also protected siRNA against nuclease breakdown, maintaining it 
intact after incubation in serum [65]. Besides, chitosan-glutamate of 470 kDa (DD = 86%) 
demonstrated significant gene silencing effect following transfection of CHO K1 or HEK 293 cells 
with chitosan/TPP/siRNA nanoparticles (82%), compared to the LMWC of 160 kDa. Moreover, the 
observed effect was comparable with that of Lipofectamine 2000 [67].  
Although in some cases results reported in different studies are not coincident, and on 
occasions are even contradictory, which is probably a result of different assay conditions in general, 
it is worth noting that chitosan with Mw below 10 kDa failed to form siRNA complexes, which can 
be attributed to shorter and stiffer chitosan chains that restrict inter-winding [80]. This contradicts 
what has been observed for pDNA, where LMWC is generally recognized to mediate higher gene 
transfection [83-85].  
 
3.2. Effect of chitosan deacetylation degree 
The contribution of DD to particle formation and, consequently, to the resultant gene 
silencing effect is related to the steric hindrance provided by chitosan molecules, where the bulky 
acetyl groups (lower DD) minimize siRNA binding to chitosan. As a result, particle stability 
decreases, leading to premature siRNA release and even lower protection against serum proteins 
[86]. This lower DD, which confers less charge intensity, further explains the formation of less 
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compact and spherical structures, by virtue of weaker ionic interactions between polyelectrolytes 
[27]. Despite the higher cell viability observed at lower DD, reduced epithelial penetration mediated 
by the opening of tight junctions in Caco-2 cells was also found [87]. In addition, high DD results in 
highly stable particles and, consequently lower siRNA disassembly. These consequences impair 
efficient gene transfection. Taking into account that chitosan degradation kinetics increase with the 
extent of acetylation, therefore, an adequate DD is required to achieve a balance between the 
degradation rate and stability of chitosan complexes as well as to provide a more controlled release 
of siRNA [2,29,30,87]. Liu et al. studied the effect of chitosan DD (54-95%) on gene transfection 
efficiency. It was found that siRNA complexes formulated with chitosan of higher DD exhibited 
higher gene transfection, whereas those prepared with chitosan of the same Mw but lower DD, 
exhibited trivial gene regulation [80].  
More than affecting the gene silencing effect, DD has been shown to influence cellular 
uptake. Interestingly, at a specific DD (70% deacetylated chitin), chitosan has also been shown to 
provide adjuvant properties for macrophage stimulation [88].  
 
3.3. Effect of chitosan type 
Techaarpornkul et al. reported that siRNA complexes produced with chitosan hydrochloride 
and chitosan acetate exhibited slightly better stability compared to those made of chitosan glutamate 
and aspartate. The chitosan salt form affected both complex size and zeta potential. Nonetheless, at 
a specific weight ratio, it had only a trivial effect on transfection efficiency. Complexes based on 
different salts (hydrochloride, glutamate, acetate, aspartate) showed a comparative level of gene 
knockdown, which was higher than that of the chitosan acetate control [79]. Katas et al. found that 
chitosan-glutamate induced considerably higher transfection levels after siRNA delivery into both 
HEK 293 and CHO K1 cells, compared to chitosan-hydrochloride. This could be attributed to the 
smaller size of the nanoparticles made of chitosan-glutamate, although it had larger Mw [67]. 
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3.4. Effect of mass or N/P ratio  
Contrary to what has been experienced with chitosan/pDNA complexes, some studies have 
shown that high mass or N/P ratios of chitosan/siRNA are needed in order to obtain complete 
nanocomplexes displaying low zeta potentials. These findings strongly indicate that the siRNA 
mechanism of binding to chitosan is distinct from that of pDNA. This is reflected in the easier 
pDNA binding to chitosan compared to that of siRNA, which could be explained by the difference 
in size and structure between both molecules. It is postulated that pDNA is easily wrapped up with 
chitosan chains, whereas siRNA is short and has a rigid structure, which protrudes out of the 
chitosan chains and, thus results in less positive net surface charge [17,71]. 
Furthermore, high mass or N/P ratios contributed to increment the positive charge, which led 
to more stable complexes with more compact structures (smaller sizes) [16,81,89]. This property 
substantiated and prolonged transfection effect; a consequence that could be attributed to the higher 
number of complete complexes entering cells, followed by higher siRNA amount released in the 
cytosol. Furthermore, the higher stability of these complexes, owing to stronger binding to siRNA 
achieved at higher ratios, may also clarify this effect. Conversely, complexes at lower ratios display 
a faster release due to less binding strength. In addition, the more efficient transfection, for 
chitosan/siRNA complexes at higher ratios, could be a consequence of higher cell internalization 
that precedes the antisense activity. For instance, Liao et al. noticed more prominent internalization 
of chitosan/siRNA complexes at higher ratios in human fibrosarcoma cells [26]. Techaarpornkul et 
al. also found substantially higher transfection for complexes at the mass ratio of 32 compared to 
those at 4, in EGFP-expressing Hela cells [79]. Similarly, Liu et al. found a greater knockdown of 
the same gene at N/P of 50 and 150 than that of 2 and 10 in EGFP-expressing H1299 cells [80]. 
Others have also reported the same conclusion with different chitosan formulations and cell lines, as 
well as in vivo [16,22,26,89]. However, greater ratios have been described to induce cell toxicity due 
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to increased positive charge of the carrier or high concentration of the polymer [26,65,90]. Hence, 
optimal mass or N/P ratio should not only refer to transfection efficiency, but also to a satisfactory 
toxicity feature. On the other hand, increasing chitosan concentration relative to that of siRNA 
implies increased mass or N/P ratio, which has been demonstrated to be accompanied by a decrease 
in particle size, probably the increased polymer amount leads to tighter complexes [16,81,89-91]. In 
other words, increasing siRNA concentration decreases this ratio, resulting in increased particle size 
which may be due to increased siRNA bond-forming bridges between chitosan chains, consequently 
leading to greater chitosan incorporation [65]. On the contrary, Katas et al. observed size increment 
for nanoparticles at higher chitosan concentrations or chitosan/siRNA weight ratios, using different 
Mw and types of chitosan. Moreover, nanoparticles exhibited higher physical stability when 
chitosan/siRNA weight ratio approached 100:1 [67]. Also, Lee et al., noticed the same tendency 
where particle size increased along with increased weight ratio of siRNA nanoparticles, composed 
of chitosan (470 kDa, DD = 86%) and polyguluronate [17]. However, these studies did not address 
the effect of the obtained weight ratios on transfection efficacy. 
According to all that has been commented on, it is suggested that the mass or N/P ratio 
greatly influences gene transfection through controlling particles’ size, surface charge and binding 
strength. Nonetheless, this ratio must be appropriately optimized in order to accomplish an adequate 
transfection level without deleterious toxic effects.  
 
3.5. Effect of pH 
The pH of both siRNA formulation and culture medium has also been described to affect 
transfection kinetics by controlling the binding events between siRNA and chitosan, which 
determine the complex stability and, therefore, siRNA release rate. For instance, at a lower pH, 
chitosan presents a higher charge density, due to amine protonation, extendedly favoring the 
flexible-like structure, owing to the repulsion between its protonated amines. This chitosan 
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conformation allows more binding contacts with siRNA, resulting in stronger interactions and 
leading to globular, compact and stable complexes. In contrast, at a higher pH, deprotonation 
prevails and chitosan conformation changes due to the collapse of electrostatic interactions, 
resulting in weaker binding to siRNA, with consequent faster siRNA release [77].  
Mittnacht et al. reported that the pH had no effect on particles size [82]. Contrastingly, other 
studies demonstrated that a pH modification markedly influenced the size, zeta potential and 
physical stability of chitosan or trimethyl chitosan/siRNA nanoparticles [27,81]. A study by Laroui 
et al. evidenced the dependency of the size of chitosan/siRNA complexes on the pH as well [92]. 
On the other hand, Katas and Alpar observed that the particles’ surface charge increased 2-fold to 
+40 mV when the pH of chitosan solution changed from 6 to 4, without observing a significant 
difference on particles size in this range of pH [67]. Nevertheless, the nanoparticles obtained at pH 
4.5 were the smallest in size, which supports the idea that chitosan amines are mostly protonated, 
hence binding more tightly to siRNA and resulting in smaller sizes. Taking into account that pKa of 
chitosan is around 6.5, Rojanarata et al. showed that the inhibition of gene expression was 
dramatically decreased for chitosan-lactate/siRNA complexes when the pH of culture medium 
increased up to 7.2. This effect was mitigated by complexing the siRNA with a chitosan derivative, 
which resulted in a more stable system that induced higher gene inhibition [16]. 
 
4. Nanocarrier-based siRNA delivery using native chitosan 
Chitosan has been directly complexed with siRNA to prepare suitable formulations for gene 
transfection. For instance, Liu et al. transfected enhanced green fluorescent protein (EGFP)-
expressing H1299 human lung carcinoma cells with chitosan/siRNA (chitosan Mw = 114 and 170 
kDa, chitosan DD = 84%; N/P = 50 and 150) complexes, which resulted in an efficient gene 
knockdown (80%), comparable to that of the TransIT-TKO siRNA Transfection Reagent [80]. 
Using the same cell line and chitosan with the same molecular weight (114 kDa, 84%), the above 
21 
 
group reported thereafter similar results in the presence of serum and with 50 nM of EGFP-siRNA 
(77.9%, N/P = 57), at 48 hours post-transfection. Similar results were also attained in primary cells 
harvested from EGFP-transgenic mice (86.9%, N/P = 36), thus being the first study on transfecting 
primary cells with a polycation-based system (N/P = 57). This also resulted in 90% knockdown of 
BCR/ABL-1 oncogen protein, following transfection with the therapeutic BCR/ABL-1 siRNA in 
K562 cells (human myelogenous leukemia line) [65]. These complexes (350-450 nm, N/P = 36) 
further down regulated tumor necrosis factor (TNF-α) in systemic and peritoneal macrophages and, 
consequently, arrested joint swelling in collagen-induced arthritic mice, following intraperitoneal 
injection. Besides, the use of 2′-O-Me-modified siRNA did not induce the innate immunity in 
macrophages, compared to its unmodified counterpart [93]. 
It is worth noting here that they also modified the EGFP-siRNA with locked nucleic acid 
(LNA) to increase its stability. Similar to the previous experiment, the same chitosan complexes, 
containing the modified siLNA, were intranasally administered (30 μg siRNA/day for 5 days, N/P = 
7). Transfection with these complexes led to 50% knockdown of EGFP in lung mice epithelium 
compared to siLNA-mismatch control. This silencing outcome was also higher than that of the 
unmodified siRNA, as revealed in the previous study (37%). The naked siLNA did not induce 
knockdown which is presumably due to the mucoadhesive properties of chitosan. The results 
obtained in this study support the idea that, for optimal siRNA delivery, chemical modification of 
siRNA may be required in addition to a suitable carrier system [36]. 
With a view to developing inhalable RNAi-based therapeutics, this system was further 
investigated for pulmonary RNAi delivery following intranasal administration in EGFP-transgenic 
mice (Mw = 114 kDa, DD = 84%, N/P = 6). Results showed that 43 and 37% knockdown in EGFP-
expressing bronchiole epithelial cells compared to untreated mice and EGFP-mismatch control, 
respectively [65]. Following that, local lung delivery using a non-invasive intratracheal insertion of 
a nebulizing catheter, was implemented into mice (chitosan Mw = 170 kDa, DD = 84%) [94]. The 
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evaluation of aerosol lung deposition and gene silencing in H1299 cells (N/P = 57) revealed that 
aerosolization altered neither particle size nor silencing efficiency of the tested formulation at 50 
nM of siRNA, which further showed minimal effect on cell viability compared to the TransIT-
TKO siRNA Interestingly, the same transfection behavior was observed in vivo, using transgenic 
green mice, with increased particle distribution in bronchial and alveolar regions and at much lower 
siRNA amounts (EGFP silencing = 68% compared to mismatch group) compared with intranasal 
administration (N/P = 23). As seen in Figure 2, nanoparticles containing EGFP-specific siRNA, 
were able to remarkably decrease the fluorescence ratio compared to the mismatch formulation, 
naked siRNA and the non-treated group. There was no significant difference in the fluorescence 
ratio between naked siRNA and nanoparticle/siRNA mismatch treated mice [94]. Interestingly, the 
same siRNA delivery system was proposed as an easy-to-use freeze-dried formulation for potential 
biomedical applications and longer shelf-life therapeutics. The chitosan-based formulations did not 
alter their size after lyophilization in the presence of a lyoprotectant (sucrose). Moreover, the 
induced transfection effect was dependent on the siRNA concentration and on the presence of the 
lyoprotectant, in EGFP-expressing H1299 cells and proinflammatory cytokine TNF-α expressing 
RAW murine macrophage cell line. The gene silencing activity of the complexes was retained for 
up to 2 months when stored at room temperature. Moreover, in contrast to the lyophilized lipid 
formulation (TransIT-TKO siRNA), the lyophilized chitosan formulation exhibited higher cell 
viability [95]. 
In the context of local therapy, intra-tumoral administration of a chitosan hydrogel loaded 
with siRNA significantly inhibited tumor growth in melanoma (72%) and breast tumors (92%) in 
mice, compared to the control [96]. Besides, chitosan/siRNA nanoparticles enhanced docetaxel 
cytotoxicity and tumor growth inhibitory effect when used as a combination therapy in ovarian 
cancer cell lines (SKOV3ip1 and HeyA8), where remarkable tumor growth inhibition was observed 
compared with the control (81.8% reduction in SKOV3ip1, P = 0.017; 84.3% reduction in HeyA8, 
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P < 0.05). These effects were mediated by decreased tumor cell proliferation and angiogenesis, and 
increased tumor cell apoptosis. Additionally, using chitosan/siRNA systems for dual silencing of 
Src and Fgr, which are members of the tyrosine kinase gene family over expressed in malignancies, 
resulted in the greatest reduction in tumor growth in vivo (68.8%, P < 0.05), compared with 
silencing of either Src or Fgr alone in the HeyA8 model [97].  Another work elucidated the potential 
application of chitosan complexes in angiogenesis treatment, using a siRNA targeting vascular 
endothelial growth factor-A (VEGF-A), which plays a critical role in angiogenesis. In vitro 
transfection of breast cancer cells (MCF-7 and MDA-MB435) revealed the highest (60%) and 
lowest (29%) gene inhibition, measured in each of the cell lines, respectively [98]. Next, intra-
tumoral and intra-peritoneal injections of these complexes were applied to breast tumor-bearing 
rats. Compared to intraperitoneal injection, the intratumoral led to higher VEGF inhibition which 
also coincided with higher tumor volume suppression (96%), measured during 36 days. As 
expected, free shRNA injection resulted in lower tumor suppression [98]. Concerning drug 
resistance to anti-tumor drugs, chitosan/pshRNA plasmid complexes targeting MDR1 genes were 
transfected in paclitaxel-resistant ovarian cancer cells (A2780/TS). The complexes exhibited 80-120 
nm diameters and could efficiently reverse resistance to paclitaxel in a time-dependent manner, 
reaching up to 61.3% as evaluated by an MTT assay. This was also consistent with the reduced 
MDR1 mRNA level of 52.6%, 7 days after transfection [66]. Chitosan/siRNA complexes (114 kDa, 
DD= 84%) prevented radiation-induced fibrosis by intraperitoneal injection targeting TNF-α in 
macrophages of mice, without revealing any cytotoxic side effects after long-term administration. 
Furthermore, TNF-α targeting was selective without a significant influence on tumor growth or 
radiation-related tumor control probability [99]. In another study, these complexes loaded with 
FHL2 siRNA (FHL2 belongs to the four-and-a-half-LIM protein (FHL) family which has a role in 
tumorigenesis) could knock down about 69.6% of FHL2 gene expression in human colorectal 
cancer Lovo cells, which is very similar to the 68.8% produced when siRNA was transfected with 
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Lipofectamine®. This specific gene down-regulation resulted in inhibition of cell growth and 
proliferation [100].  
Kong et al. developed a vaccine for the respiratory syncytial virus (RSV), which causes 
severe bronchiolitis and is deemed a risk factor for asthma. The vaccine is comprised of chitosan 
(Mw = 110 kDa) complexes containing siRNA targeting RSV-NS1 gene (siNS1), whose protein 
seemingly antagonizes the host TNF-α. Histological and bronchoalveolar lavage assays showed that 
the prophylactic use of siNS1 may be an effective method for preventing RSV bronchiolitis, while 
potentially reducing the later development of asthma associated with severe respiratory infections 
[101]. On the other hand, chitosan oligomers were administered intranasally to deliver siNS1 in 
mice. The complexes administered either after or before RSV infection could markedly knockdown 
the NSI protein, resulting in considerable reduction in virus titers in the lung, as well as in the 
attenuation of the airway inflammation and reactivity compared to the controls [102].  
Several chitosan/siRNA delivery nanosystems were prepared in the presence of the physical 
cross-linker, TPP, using ionotropic gelation. It is assumed that this agent helps in the reticulation or 
solidification of the polymeric networks, thus stabilizing the nanoparticulate entity and increasing 
macromolecule entrapment, as well as ensuring its protection [67]. TPP had been shown to have no 
effect on transfection efficiency of chitosan-based siRNA nanoparticles as previously reported [27]. 
On the contrary, Wang et al. showed that TPP inclusion, in chitosan/shRNA nanoparticles, resulted 
in significant EGFP-silencing efficiency (80%) in human embryonic rhabdomyosarcoma cells (RD) 
compared to chitosan/shRNA complexes (chitosan glutamate, Mw = 460 kDa, DD = 86%), thus 
being comparable to Lipofectamine® as well [68]. Chitosan nanoparticles could further down 
regulate TGF-1 gene, overproduced by RD cells, after subcutaneous injection in nude mice. 
Notably, modified tumorigenicity resulted in a decrease in tumor volume to 45.5% after 2 weeks of 
therapy [68].  
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In support of these findings, in an interesting work, Katas and Alpar compared the 
nanoparticles prepared using two methods of ionic cross-linking, simple complexation and ionic 
gelation with the physical crosslinker TPP (chitosan glutamate: Mw = 470 and 160 kDa; chitosan 
hydrochloride: Mw = 270 and 110 kDa; DD = 86%). In vitro studies in two types of cell lines (CHO 
K1 = Chinese Hamster Ovary cells, and HEK 293 = Human Embryonic Kidney 293 cells), revealed 
that preparation method of siRNA association to the chitosan plays an important role on the 
silencing effect. In fact, the transfection, carried out in 5% serum, revealed notably better biological 
activity of siRNA entrapped in chitosan/TPP nanoparticles (82%), compared to either siRNA 
adsorbed on these nanoparticles (63%) or simply complexed to chitosan (51%) without TPP. In 
addition to the effect of the preparation method and mixing manner of reagents on the transfection 
level, the study also highlighted that specific siRNA down regulation was higher after 24 hours than 
48 hours. These results could be justified by the higher stability of chitosan nanoparticles, as 
assessed in 5 and 50 % serum, as well as by the higher protection provided to siRNA, which is 
prone to degradation when adsorbed on the nanoparticles surface. Surprisingly, chitosan 
nanoparticles caused transient cell toxicity compared to chitosan complexes, although individual 
chitosan and TPP solutions exhibited biocompatibility. This is apparently due to the higher chitosan 
concentration used to transfect the cells in the form of nanoparticles (5.3 μg) compared to that of 
chitosan complexes (0.53 μg) [67]. 
Chitosan/TPP nanoparticles were also loaded with siRNA targeting relaxin (RLN), which is 
a small peptide hormone expressed in several cancers of reproductive and endocrine organs. 
Increased expression of RLN in prostate cancer correlates with aggressive cancer. RLN behaves as 
a cell growth factor and increases invasiveness and proliferation of cancer cells in vitro and in vivo. 
Intratumoral injection of these nanoparticles, into prostate cancer-bearing mice, resulted in 60% 
reduction of RXFP1 mRNA at 48 hours post-injection. Excitingly, this treatment effectively 
suppressed tumor growth and reduced tumor size in vivo, being associated with decreased cell 
26 
 
proliferation and increased apoptosis, as well as considerable decrease in metastasis rate in 
androgen receptor-negative prostate cancer cells (PC3). Furthermore, the suppression of RLN 
signaling significantly reduced metastasis rates. Global transcriptional profiling of PC3 cells treated 
with RXFP1-siRNA further revealed genes with markedly altered expression profiles, which have 
been previously documented to promote tumorigenesis [103]. Ultrafine chitosan/TPP nanoparticles 
of 20 nm also exhibited excellent transfection efficiency in Neuro2a mouse neuroblastoma cells 
evidencing feasibility as neurotherapeutics [81]. In another work, chitosan/TPP nanoparticles, 
loaded with siRNA targeting muscarinic acetylcholine receptor subtypes, were intrathecally injected 
into rats for 3 consecutive days. Treatment produced a large reduction of the corresponding mRNA 
levels (50-60%) in the dorsal root ganglion and spinal cord, leading to a marked reduction in the 
anti-nociceptive effect of muscarine. The encouraging findings attained in this regard paved the 
road to a new approach of chronic pain treatment in neuronal tissues, using antisense therapy 
assisted by chitosan nanoparticles [104,105]. 
 
5. Nanocarrier-based siRNA delivery using chitosan derivatives 
Chitosan poor solubility at physiological pH and its limited buffering capacity are the main 
incentives that have encouraged research to find alternative derivatives of this polymer. Some of 
these derivatives display ameliorated solubility within a wide range of pH so that chitosan 
nanocarriers possess better stability in the physiological environment [16], particularly against 
nucleases. Furthermore, the use of these derivatives is expected to potentiate in vivo transfection 
kinetics with respect to both efficiency and sustained gene silencing. To this end, structural 
modifications of chitosan have been explored, such as quaternization of the amine group [27,91] and 
the introduction of functional groups [82,91] as well as conjugation with other polymers [78] or 
ligands [78,106]. In this regard, chitosan derivatization has been shown to create safer and more 
efficient gene vectors [78]. Generally speaking, this strategy has been advantageous not only from 
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the perspective of drug delivery, but also for broadening the biomedical applications of this polymer 
[107]. 
One of the reasons for chemical modification of chitosan lies in the necessity of improving 
endosomolysis of chitosan/siRNA complexes. Thereby, different strategies have been adopted, such 
as the use of pH sensitive polyelectrolytes (cationic or anionic) that possess a high proton “sponge 
effect” [18,108], as well as the inclusion of other compounds possessing an endosomolytic effect 
[65,90] and the conjugation to some functional groups or polymers [78,91]. For instance, to 
introduce secondary and tertiary amines into chitosan in order to ameliorate its buffering capacity 
and solubility at high pH, Mittnacht et al. conjugated imidazole to chitosan (Mw = 140 kDa) to 
deliver siRNA [82]. In addition to cell biocompatibility in a neuronal cell model (PC12 cells), this 
derivative interestingly manifested homogenous particle distribution in the cell, suggesting efficient 
endosomal escape. It induced 65-75% degradation of the target mRNA. However, it did not show a 
better knockdown efficiency than the unmodified chitosan, as previously experienced with pDNA 
[108]. On the contrary, Ghosn et al. used the same vector to deliver siRNA and reported higher gene 
knockdown compared to native chitosan, which was also equivalent to that of the commercially 
available siPORT Amines. These outcomes were further corroborated in mice after intranasal 
administration, where silencing activity reached up to 60% in lung tissue [109]. 
Trimethylation of chitosan may provide some beneficial characteristics to siRNA delivery, 
such as increased stability, due to enhanced solubility at physiological pH and an increased positive 
charge, which assists siRNA cellular uptake while improving the buffering capacity and 
mucoadhesive properties [110]. Nevertheless, trimethylchitosan (TMC)/EGFP-siRNA complexes, 
demonstrated low transfectivity in EGFP protein expressing HEK 293 cells at 50 nM of siRNA. 
This poor transfectability may be accounted for the highly stable complexes in which siRNA 
disassembly was not facilitated from its carrier. Nevertheless, transfectivity was significantly 
different from that of native chitosan, which is likely due to the higher positive charge of TMC that 
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led to enhanced cellular uptake compared to that of chitosan/siRNA complexes [27]. No noteworthy 
effect for the degree of chitosan quaternization was noticed on the silencing activity, which is 
consistent with other works [18]. On the other hand, chitosan trimethylation slightly reduced 
chitosan viability which contradicts other findings in different cell lines [91]. 
In an effort to promote the endosomolytic activity of TMC, which has a limited buffering 
capacity, either the membrane-disruptive peptide diINF-7 was added to the formulation or 
photochemical internalization (PCI) was applied. The latter technique is based on the use of a 
photosensitizer that locates itself in the endosomes upon incubation with the cells, causing 
photochemical destabilization of endosomal membranes after illumination, with subsequent release 
of endocytosed material into the cytosol. The use of both strategies in transfection of luciferase 
expressing H1299 cells improved the silencing outcome, demonstrating that this chitosan derivative 
greatly benefited from the enhancement of endosomolysis. This chitosan derivative also showed 
low cell toxicity, as well as evidenced retained silencing activity in the presence and absence of 
serum [91]. Besides, the same group suggested a technique for promoting cellular uptake, which 
does not rely on a surface charge density but rather on the formation of a disulfide bond with mucin 
glycoproteins on the cell membrane. Thiolation of N,N,N-trimethylated chitosan interestingly 
demonstrated substantial gene silencing compared to non thiolated counterparts in a dose dependent 
manner (60-89% vs 40%, respectively), in luciferase expressing H1299 cells (N/P = 8) [90]. 
Notwithstanding that this finding is in line with other observations [89,111], it contradicts what has 
been reported that siRNA silencing activity is independent on the siRNA concentration after 
transfection with chitosan/siRNA complexes using the same cell line (50-200 nM) [65,95]. 
Likewise, in contrast with non-thiolated formulations, the thiolated counterparts retained their 
silencing activity even in the presence of hyaluronic acid, illustrating the enhanced stability of these 
complexes against competitor anionic macromolecules present in the body, certainly, due to 
thiolation. The enhanced stability and, thus, biological activity after thiolation might be explained 
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on the basis that the formation of reducible disulfide bonds between thiol groups leads to increased 
extracellular stability and improved intracellular release properties. On the other hand, the 
cytotoxicity profile was the same for the thiolated and non-thiolated formulations and more 
favorable compared to that of the used commercial agent, Lipofectamine. These findings point out 
the suitability of thiolated TMC as a gene vector before proceeding to animal experiments [91]. 
Eudragit® S100, which is a pH sensitive and membrane-destabilizing polyelectrolyte, was also 
proposed for improving the buffering capacity of TMC. The incorporation of this polyelectrolyte 
improved transfection efficacy of TMC/siRNA complexes, which could be ascribed to the proton 
sponge mechanism combined with the endosomal membrane rupture. This may occur as a 
consequence of complex swelling and/or Eudragit conformational change, mediated by the 
protonation of its carboxylic group, under the acidic conditions found in the endosome [18]. 
Notwithstanding the improvement of the endosomolysis attained by the application of the 
described chitosan derivatives, the endosomolytic property of native chitosan has been verified 
when the endosomolytic agent, chloroquine, did not affect the silencing level of chitosan/siRNA 
formulation transfected into EGFP expressing H1299 cells [65]. The obtained gene knockdown was 
≈ 78% at 50 nM siRNA in the absence of serum, which was similar to that of thiolated TMC (80%) 
in the same cell line. The N/P ratio of the complexes and the Mw of chitosan used were quite 
different in these studies. Despite the difficulty in comparing results, due to differences in the 
transfection protocols of both studies, this may emphasize the ensodomal escape mechanism 
endowed by native chitosan, as the chitosan/siRNA complexes achieved good gene silencing in 
mice after intratracheal administration, as mentioned above [65,91]. 
Low Mw polyethyleneimine (PEI) (25 kDa) was grafted onto chitosan which was then 
complexed with shRNA or siRNA resulting in compact and stable complexes that enhanced 
intracellular uptake in A549 cells. Using a therapeutic shRNA, this chitosan derivative could 
successfully silence the oncoprotein at both mRNA and protein level, which displayed a better 
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safety record over the unmodified PEI. This highlights that this conjugation shielded the high 
positive charge of PEI which is responsible for its known toxicity. Moreover, cell malignancy and 
metastasis were significantly reduced, as revealed by a soft agar gel assay, and induced apoptosis 
and reduced cell proliferation were detected [112]. In spite of these outcomes, this system is still 
lacking cancer cell specificity Thus, to potentiate an in vivo application, the same group further 
conjugated the system with a folate ligand. Most impressively, the folate-chitosan-g-
polyethyleneimine vector exhibited better cell viability even at a high concentration, compared to 
the standard PEI. Moreover, it exhibited enhanced gene transfer efficiency and cancer cell 
specificity in vitro, mediated by folate receptor endocytosis. When investigating the potential of the 
system in vivo, the nebulization of Akt1 shRNA complexes significantly suppressed lung cancer 
development in urethane-induced lung cancer model mice, suggesting the utility of this carrier for 
aerosol gene delivery [78]. 
Another work reported the modification of PEI and glycol-chitosan (GC) with hydrophobic 
5β-cholanic acid, afterwards being self-assembled into nanoparticles via strong hydrophobic 
interactions of 5β-cholanic acid in both polymers [38]. The glycol derivative showed, in previous 
studies, both a targeting ability and biocompatibility, being used as a carrier for anti-cancer agents 
[113]. Since siRNA condensation depends on ionic interactions, it was however difficult to 
condense siRNA with this carrier due to its insufficient charge density, which has been reported to 
be indispensible for complex formation and stability [16]. Therefore, PEI was employed to confer a 
strong positive charge, taking into consideration its recognized capability of gene transfection, 
which is attributed to “proton sponge” effect. The siRNA, complexed with PEI-GC, displayed a 350 
nm size and a zeta potential of +23.8 mV, as well as increased biocompatibility, compared to PEI, 
as assessed in B16F10 tumor cell expressing red fluorescent protein (RFP) (RFP/B16F10). The 
complexes featured a distinguishable protecting effect to siRNA against RNase degradation at a 
weight ratio of 5:1 for PEI-GC/siRNA. In these cells, the newly developed complexes showed rapid 
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time-dependent cellular uptake within 1 hour and a substantial RFP knockdown, estimated as 82% 
of the cleaved specific mRNA, after 1 day post-transfection and at 200 nM of siRNA. Furthermore, 
the complexes revealed a high targeting ability to tumor cells in RFP/B16F10-bearing mice, 
accompanied with significant RFP silencing, following intravenous injection of 50 μg siRNA 3 
times every 2 days. In contrast, free siRNA was rapidly excreted from the kidneys within 1 hour 
post-injection, whereas PEI/siRNA complexes showed non-specific localization by high and rapid 
accumulation in the spleen and liver, thus being cleared rapidly providing lower knockdown (Figure 
3). As expected, these outcomes resulted from the high protection to siRNA in the serum, as well as 
from the efficient cellular uptake and the endosomal escape provided by the designed carrier [38]. 
Low molecular weight PEI (25 kDa) was blocked with polyethylene glycol monomethyl 
ether (mPEG) and, then grafted onto chitosan to synthesize a ternary cationic copolymer for siRNA 
delivery purpose. Due to both mPEG and chitosan, cell viability of the new vector was ameliorated 
compared to PEI itself. In comparison to free siRNA, the vector provided protection to the molecule 
after incubation in 10% serum, particularly at higher N/P ratios. Concerning gene silencing, the 
transfection of HeLa cells and human Tenon’s capsule fibroblasts (HTFs) with 50 nM siRNA 
resulted in a substantial suppression of mRNA levels of IκB kinase beta (IKKβ) with subsequent 
inhibition of the nuclear factor kappa B (NF-κB) activation, being associated with the suppression 
of HTFs proliferation [89]. A subconjunctival injection of this system, at the time of surgery and 7 
days post surgery (N/P = 10 and 50 nM), was well tolerated in a monkey model of trabeculectomy. 
Furthermore, 60 days after surgery, a marked reduction in subconjunctival scar tissue was observed, 
compared with the eyes of the group treated with phosphate buffer saline. This was also 
accompanied with a healthy conjunctival epithelium without the acellularity detected in the 
mitomycin C-treated group (positive control). Due to the ameliorated surgical outcomes, this siRNA 
complex-mediated blockage of signaling pathway represents a novel approach, which is potentially 
a more controlled alternative as an anti-scarring agent in glaucoma filtration surgery [111]. 
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Recently, a new multifunctional magnetic nanovector was developed for dual imaging and 
therapeutic purposes. It is comprised of a superparamagnetic iron oxide nanoparticle core, coated 
with polyethyleneglycol-grafted chitosan and PEI. siRNA and a tumor targeting peptide, 
chlorotoxin, were covalently attached to this construct, which constitutes a tool for non-invasive 
monitorization of siRNA delivery in real-time by means of magnetic resonance imaging. A 
significant EGFP silencing mediated by the targeted nanoparticles (62%) was observed 48 hours 
after transfection of EGFP-expressing C6 rat glioma cells, compared to the non-targeted 
homologues (35%) and other controls. Apparently, PEI inclusion enhanced the endosomolysis and 
the pegylated chitosan circumvented PEI cytotoxicity. It was then demonstrated that the targeted 
nanoparticles were internalized through a receptor-mediated mechanism, which can ensure that a 
greater percentage of cells receive an effective dose of siRNA whilst adsorptive mediated-
endocytosis is a non-specific pathway for non-targeted vectors. This clarifies the higher silencing 
effect of chlorotoxin-targeted nanoparticles [25. In the context of tracking siRNA mobility during 
its delivery, the superparamagnetic iron oxide core was also coated with chitosan, conjugated to 
linoleic acid as a hepatocyte targeting moiety. Interestingly, an in vivo study performed in mice 
using magnetic resonance (MR) imaging, revealed selective accumulation of the nanoparticles in 
hepatocytes within a few minutes after intravenous injection (Figure 4), these being associated with 
efficient GFP knockdown and evidencing biocompatibility [106].  
Another formulation of self-tracking nanoparticles based on chitosan (200 kDa) was 
devised. These nanoparticles, encapsulating fluorescent quantum dots (QD), were further 
conjugated to siRNA targeting human epidermal growth factor receptor 2 (HER2). HER2 antibody 
and siRNA were conjugated onto the nanoparticles to treat breast cancer (both the delivery and 
transfection of siRNA can be monitored by the presence of the fluorescent QD in the chitosan 
nanoparticles). Compared to the non-targeted vehicles, targeted nanoparticles demonstrated 
considerable gene silencing in both HER2-overexpressing MCF-7 and SKBR3 cells; the effect 
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being more pronounced in the latter cell line, as these cells express larger numbers of HER2 
receptors. This result was also confirmed by the higher cellular uptake, which was receptor-
mediated, for the negatively charged and targeted nanoparticles. The study, however, does not 
tackle the cytotoxicity aspect of this promising delivery system, a relevant detail, as it includes 
quantum dots [114].  
An Arg-Gly-Asp (RGD) peptide was conjugated to chitosan by a thiolation reaction, as 
another platform for targeted siRNA delivery. The ability of this vector to bind the 3 integrin 
was examined to ensure its potential targetability. The RGD-chitosan/siRNA complexes 
significantly increased the selective intratumoral delivery in orthotopic mice models of ovarian 
cancer. Additionally, targeted silencing of multiple growth-promoting genes (POSTN, FAK, and 
PLXDC1) along with therapeutic efficacy in SKOV3ip1, HeyA8 and A2780 cell models were 
verified using this vector. Tumor vascular targeting was further validated in vivo by delivering 
PLXDC1-targeted siRNA into the alphanubeta3 integrin-positive tumor endothelial cells in the 
A2780 tumor-bearing mice. The developed delivery system enormously inhibited tumor growth 
compared to the controls [115]. 
Poly-L-arginine (PLR), a biodegradable cationic polymer, was conjugated with chitosan, 
which was further pegylated [22]. This approach aims at enhancing, on one hand, the cationic 
charge of chitosan, thus potentiating its transfectability; and, on the other, improving the 
cytotoxicity of PLR by conjugation to chitosan. PLR has been described to mediate cellular uptake 
through its interaction with sulfated proteoglycans and cholesterol [116]. Chitosan complexed to 
siRNA showed a poor silencing efficiency compared to LipofectamineTM2000, chitosan-PLR and its 
pegylated counterpart, although it provided the best cell viability. All complexes composed of 
chitosan-PLR demonstrated the highest gene silencing either in cells or in vivo after intratumoral 
injection to mice [22]. Considering that stability in serum is a valuable property of delivery systems 
towards future application in vivo, it is important to note that complexes based on the pegylated 
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chitosan-PLR showed high gene silencing in cells without dependency on serum (N/P = 12), 
evidencing the best in vivo results as well (Figure 5). This higher serum stability could be accounted 
for by the shielding effect of pegylation, precluding the interaction with serum proteins and RNase 
digestion. 
Another carrier has been reported consisting of chitosan conjugated to thiamine 
pyrophosphate, which is a water soluble vitamin that plays a role in the cell’s energy supply, 
displaying no toxicity. It assists nanoparticles formation as it reinforces the charge interaction via its 
negatively charged phosphate group that neutralizes the positive amine of chitosan during 
complexation, as well as its amine of thiazolium that remains positive even at physiological pH. 
This property compensates the positive charge loss of chitosan amines at this pH by interacting with 
siRNA via charged amines of thiazolium and, thus, maintaining the electrostatic interactions that 
ensure complex stability and, consequently, high gene transfection. This structural modification led 
to higher EGFP knockdown (70-73%) in EGFP-HepG2 (human hepatocarcinoma) cells compared 
to the unmodified conventional chitosan lactate (40-50%) at the same mass ratio. This higher 
transfectability attained at three days post-transfection was comparable with that of the commercial 
agent, being slightly affected at pH 7.2, which suggests higher stability provided by conjugation 
with this vitamin. More importantly, this system manifested high cell viability at different Mws of 
chitosan (20-460 kDa) and chitosan/siRNA weight ratios (0.4-80) [16. 
 
6. Nanocarrier-based siRNA delivery using chitosan in polymeric combinations 
Unlike chemical modification of chitosan, researchers have envisaged the design of siRNA 
vectors through constructing polymeric combinations from chitosan and other polymers, taking 
advantage of combinatory effects that may substantiate transfectivity. This type of combination is 
mostly mediated by ionic interactions between chitosan and the other polymer. For instance, siRNA 
nanoparticles were prepared using chitosan (Mw = 470 kDa, DD = 86%) and polyguluronate (Mw = 
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6 kDa), which was isolated from alginate (Mw = 200 kDa). The rational for this polymeric 
combination was to enhance gene transfection through producing lower sized-nanoparticles, as 
direct complexation between chitosan and alginate often results in large particles owing to the high 
Mw of both polymers. Interestingly, in this study, all the chitosan-based siRNA nanoparticles 
featured high cell viability compared to that of Lipofectamine. In the presence of 20% serum, gene 
knockdown was greater for complexes containing polygurunate than for those including either 
alginate or chitosan alone, in HEK293FT and HeLa cells. This greater transfection was comparable 
to that of Lipofectamine and poly (L-lysine), which is likely due to the smallest sizes and higher 
stability of complexes combining chitosan with polygurunate [17]. 
Chitosan (Mw = 80 kDa, DD = 85%) and poly (γ-glutamic acid) (Mw = 20 kDa) were also 
combined to deliver siRNA to human fibrosarcoma cells. The rational for this ternary chitosan/ 
siRNA/poly(γ-glutamic acid) combination was to trigger complex unpackaged as chitosan/siRNA 
complexes proved to remain stable in the cytosol at pH 7, enabling a later disruption via enzymatic 
degradation. Relative to the untreated cells, these ternary complexes exhibited considerably higher 
cellular uptake (96%) than those of chitosan/siRNA (82%); an effect being enhanced with 
increasing poly(γ-glutamic acid) content in the complexes. This behavior accounts for the 
significantly higher gene silencing compared to chitosan/siRNA complexes. According to 
transfection kinetics, the ternary combination expedited siRNA release in the cytosol leading to a 
faster onset of gene silencing (80% at 48 hours), which was prolonged up to 72 hours. These 
findings indicate the changes in the mechanism involving transfection after incorporating another 
polymer into the chitosan/siRNA complex [26].  
Another study reported the combination of chitosan-g-PEG with hyaluronic acid via ionic 
gelation, producing nanoparticles that revealed minimal toxicity and improved stability in 50% 
serum. Furthermore, they could specifically and efficiently knockdown the Snail transcription 
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factor, a mediator of tumor invasion, in HEK 293 T cells expressing the fusion EGFP-Snail protein, 
using two types of siRNA targeted to EGFP and Snail protein [117]. 
The anionic methacrylic acid copolymer (MAA) (Eudragit® S100) was also employed to 
prepare an interpolyelectrolyte complex with TMC for siRNA delivery. The presence of MAA did 
not affect the incorporation of siRNA to the complex, though it led to complex instability owing to 
charge neutralization. This complex exhibited a larger size, higher cell uptake and mRNA reduction 
compared to TMC/siRNA complex, measured in murine fibroblasts (L929 cells) 48 hours after 
transfection (50 nM siRNA). Importantly, it was also concluded that the degree of TMC 
quaternization did not affect transfection efficiency [18].  
 
7. Nanocarrier-based siRNA delivery using chitosan as an additive material 
In order to prevent the loss of the encapsulated material, chitosan has been used as a coating 
agent or a surface modifier in other delivery nanosystems, benefiting from its high affinity to cell 
membranes [118]. For instance, poly(lactic-co-glycolic) acid (PLGA) nanospheres, intended for 
lung siRNA delivery were produced by emulsion solvent diffusion and, thereafter, were coated with 
chitosan. This modification shifted the nanospheres surface charge to positive values, resulting in 
higher siRNA loading and increased cellular uptake, mediated by an improved interaction with the 
negatively charged cell membranes. Notwithstanding that uncoated PLGA nanospheres provide a 
controlled release [72], chitosan coating further reduced the burst effect from these nanospheres 
without altering the general siRNA release pattern. This resulted in a sustained release that 
maintained the silencing activity for up to 5 days in A459 cells. The reduced siRNA release, 
through chitosan coating, was also confirmed in another work [119]. The higher and more 
prolonged silencing activity provided by chitosan modification of PLGA nanoparticles could be 
also accounted for siRNA protection against nucleases [118]. Other authors working with these 
chitosan-coated PLGA nanoparticles, have found that increasing chitosan concentration led to 
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increased particle size, siRNA loading and zeta potential, which collectively influenced the 
silencing activity thereafter. The increment in zeta potential reached a plateau which was attributed 
to saturated adsorption of chitosan on the nanoparticles’ surface. Beyond 0.033% of chitosan 
coating concentration, stable nanoparticles were formed and protection to siRNA was achieved 
following incubation with RNase1, which is indicative of effective binding to siRNA. GFP protein 
knockdown in HEK 293 T cells was demonstrated to be dependent on both siRNA loading and zeta 
potential, which were also proportionally correlated with chitosan concentration where higher 
chitosan concentration corresponded to higher positive charge availability to bind siRNA, thus 
facilitating nanoparticles cellular uptake. These results yielded a silencing effect of 63.3%, in the 
case of higher siRNA loading, and > 70% for the most positive formulation (+31 mV). In addition, 
these nanoparticles further demonstrated cell viability [120]. It was also reported the increased 
PLGA nanoparticles’ size with increased Mw of chitosan. The higher Mw of chitosan renders more 
viscous the organic phase of the process, resulting in the formation of larger emulsion droplets that 
are more resistant to shear forces. As demonstrated, these particles exhibited biocompatibility in 
HEK 293 cells regardless of the Mw of chitosan used [121].  
siRNA delivery was also studied using core-shell nanoparticles composed of chitosan and 
poly (isobutylcyanoacrylate) (PIBCA), prepared by radical polymerization, which were designed to 
target a thyroid cancer oncogene (ret/PTC1). Intratumoral injection of nanoparticles every 2 days in 
tumor bearing mice resulted in 82% down-regulation for the referred oncogene, significantly 
inhibiting tumor growth compared to free ret/PTC1 siRNA (Figure 6) [122]. In another work, 
chitosan-coated poly (isohexylcyano acrylate) (PIHCA) nanoparticles were intravenously injected 
in breast cancer-bearing mice to deliver the anti-RhoA siRNA, every 3 days at a dose of  150 or 
1500 g/Kg. This treatment inhibited tumor growth by 90% in the group that received the lowest 
dose and by even more in the highest dose group. Necrotic areas were observed in tumors from 
animals treated with the highest dose, as a consequence of angiogenesis inhibition. In addition, this 
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therapy was found to be devoid of toxic effects, as evidenced by similarities between the control 
and treated animals for the following parameters: body weight gain; biochemical markers of 
hepatic, renal and pancreatic function; and macroscopic appearance of organs after 30 days of 
treatment [123]. For the same therapeutic application, other nanoparticles constituted of the 
monomers, referred to above (PIBCA and PIHCA), used individually, were coated with medium 
Mw chitosan and administered to mice bearing a papillary thyroid carcinoma. Inhibition of tumor 
growth by 64% and 59% was observed after intratumoral administration of PIBCA and PIHCA 
nanoparticles, respectively, at a dose of 1 mg/kg siRNA. Only PIBCA nanoparticles manifested 
significant tumor growth inhibition after intravenous injection (5 mg/kg siRNA), although they 
displayed a negative surface charge (-11.8 mV). This effect was attributed to their smaller size (60 
nm) and the capacity to escape from macrophage uptake [124]. 
 
5. Conclusions and Future Perspectives 
From the above mentioned comments, it is clear that chitosan and its derivatives represent 
excellent biomaterials for the preparation of siRNA nanocarriers. In this respect, special mention 
should be paid to the structural properties of chitosan, such as molecular weight, degree of 
deacetylation, salt form, as well as the eventual chemical modifications, that were observed to 
greatly affect transfectivity of siRNA molecules. Besides, formulation parameters like mass or N/P 
ratio and pH, have demonstrated to play an important role. All these factors control the 
physicochemical properties of chitosan nanocarriers in terms of size, surface charge and binding 
capacity to siRNA molecules, which, in turn, govern transfection kinetics. Nevertheless, there has 
been no decisive consensus concerning the role of each of these factors on the transfectability of 
chitosan-based siRNA nanovectors. These discrepancies may arise from differences in the type of 
cell lines, the preparation methods, as well as the relative abundance of target mRNA and the half-
life of its protein, among others. Therefore, it could be inferred that transfection efficiency is the 
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result of interplay between a number of issues related to the delivery system that should meet the 
machinery of gene silencing and the characteristics of biological environments. Despite this, 
binding strength between siRNA and its chitosan-based carrier, which is enormously dependent on 
mass or N/P ratios, must be investigated in the development of siRNA delivery systems. This 
binding must ensure efficient balance between the appropriate siRNA protection in biological 
environments and decoupling in the cytosol, prior to mRNA degradation. However, whilst 
encouraging results have been achieved in cell culture and animal models, the developed vectors are 
of limited efficacy in vivo and still need to be further adapted to enhance therapeutic output prior to 
clinical application. 
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Figure captions: 
 
 
Figure 1. Schematic illustration of the structure of chitosan. 
 
Figure 2. Flow cytometric analysis of EGFP knockdown in digested mouse lung after intratracheal 
administration of aerosolised siRNA formulations in transgenic EGFP mice (n=5, dose; ~0.26 μg in 
4 μl on day 1 and 3,tissue harvest day 5). The chitosan/EGFP-specific siRNA nanoparticles 
(NP/EGFP) showed significant knockdown compared to mismatch nanoparticle controls 
(NP/Mismatch) and naked siRNA (EGFP) determined by lower EGFP fluorescence ratio, R = 
(Number of events ×median FL1-H of EGFP-positive population) / (Number of events × median 
FL1-H of EGFP-negative population). Normalised to non-treated animals set at 100% fluorescence 
ratio. Error bars: standard error of the mean. P value denotes students t-test (P<0.05) analysis of 
respective groups, Asterix denotes significant between groups (from 94 with permission).  
 
Figure 3. A quantification of in vivo targeting characteristics of Cy5.5-siRNA and Cy5.5-siRNA–
GC–PEI NPs was recorded as total photons per centimeter squared per steradian (p/s/cm2/sr) per 
milligram of each organ at all time points (n=3 mice per group). All data represent mean ± s.e. 
(adapted from 38 with permission).  
 
Figure 4. Nuclear images (A) of mice at 30 min and 1 h after injection of 99mTc-labeled SCLNs. 
MR images (B) of the middle part of the mouse liver before and after injection of SCLNs (from 
106 with permission).  
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Figure 5. Quantitative expression of RFP in siRNAs-treated mice tumors relative to untreated 
tumors after 3 days of intratumoral administration of: naked siRNA, chitosan-PLR (CS–PLR) and 
pegylated chitosan-PLR (PEG–CS–PLR) complexes. siRNAs (siRFP and siGL2) were administered 
to the right flank of mice bearing B16F10-RFP tumors whereas tumors in the left flank were 
untreated as a control (n = 4, *: significantly different from the group treated with siGL2 delivered 
by the same carrier; P < 0.05) (adapted from 21 with permission). 
 
Figure 6. Antitumor effect of the ret/PTC1 small interfering RNA (siRNA) in the RP1 graft. 
Injections were performed on days 0, 2, 4, 7, 10 as indicated by the arrows. siRNA were dissolved 
in 0.9% NaCl. The following preparations were intratumorally injected: free siRNA #1 (siRNA #1), 
free control siRNA (Ctrl siRNA), unloaded nanoparticles (free NP), siRNA #1 associated with 
nanoparticles (siRNA #1/NP) and control siRNA associated with nanoparticles (Ctrl siRNA/NP). P 
< 0.05 versus 0.9% NaCl-treated mice ) (adapted from 122 with permission). 
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